Glucocorticoid-Induced Osteoporosis
Conditions
Interventions
Teriparatide arm: Patients receive weekly teriparatide with a discontinuation of bisphosphonate. At week 72, patients stop receiving teriparatide and are switched back to bisphosphonate. At week 144,
Sponsors
Teikyo University School of Medicine (Hajime Kono) Toho University School of Medicine (Toshihiro Nanki)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Age at 20 yaers old or more. 2) Paitnets who recieve glucocorticoid (PSL 5mg or more) and bisphosphonate more than 6 months. 3) BMD of lumber spine (L1-4) or hip (neck or total) by DEXA is T-score of -2.0 or less, or T-score of -1.0 or less who have a history of fragility fracture. 4) Written informed consent required.
Exclusion criteria
Exclusion criteria: 1) Patients whose BMD of 3 or more of lumbar spines cannot be analysed because of fracture or artificial materials. 2) Contraindication for bisphosphonate or teriparatide. 3) Patients who have received teriparatide or denosumab. 4) Patients with active infection or malignancy. 5) Age less than 20 years old. 6) Patients who is currently pregnant, breastfeeding or willing to get pregnant. 7) Patients who do not give consent to the study. 8) Patients who are judged to be inappropriate by the physician.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary outcome is the change of bone mineral density in hip and lumbar spine (L1-4). | — |
Countries
Japan
Contacts
Public ContactHajime Kono / Toshihiro Nanki
Teikyo University School of Medicine (Hajime Kono) Toho University School of Medicine (Toshihiro Nan Department of Internal Medicine (Hajime Kono) Division of Rheumatology, Department of Internal Medic
Outcome results
None listed